Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program.

PubWeight™: 1.08‹?› | Rank: Top 10%

🔗 View Article (PMC 2752378)

Published in Pediatr Blood Cancer on September 01, 2009

Authors

Nino Keshelava1, Peter J Houghton, Christopher L Morton, Richard B Lock, Hernan Carol, Stephen T Keir, John M Maris, C Patrick Reynolds, Richard Gorlick, E Anders Kolb, Jianrong Wu, Malcolm A Smith

Author Affiliations

1: Children's Hospital of Los Angeles, Los Angeles, California 90027, USA. nkeshelava@chla.usc.edu

Articles citing this

Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets. Annu Rev Pathol (2011) 1.70

Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. J Clin Oncol (2010) 1.42

Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma. Oncogene (2012) 1.20

A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma. Front Oncol (2013) 0.95

Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines. Invest New Drugs (2012) 0.88

Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development. Br J Haematol (2010) 0.86

Molecular profiling of childhood cancer: Biomarkers and novel therapies. BBA Clin (2014) 0.86

Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2013) 0.83

Rapid screening of novel agents for combination therapy in sarcomas. Sarcoma (2013) 0.81

Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res (2015) 0.81

Childhood cancer and developmental biology a crucial partnership. Curr Top Dev Biol (2011) 0.79

Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma. Oncotarget (2016) 0.77

The effect of vorinostat on the development of resistance to doxorubicin in neuroblastoma. PLoS One (2012) 0.76

Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2014) 0.76

A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program. Leukemia (2016) 0.76

JNJ-26481585 primes rhabdomyosarcoma cells for chemotherapeutics by engaging the mitochondrial pathway of apoptosis. Oncotarget (2015) 0.76

Cell Proliferation in Neuroblastoma. Cancers (Basel) (2016) 0.75

Histone acetylation: novel target for the treatment of acute lymphoblastic leukemia. Clin Epigenetics (2015) 0.75

Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK Pathways. PLoS One (2015) 0.75

p21(WAF1) modulates drug-induced apoptosis and cell cycle arrest in B-cell precursor acute lymphoblastic leukemia. Cell Cycle (2015) 0.75

Articles cited by this

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A (2000) 5.53

The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer (2007) 5.28

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol (2005) 4.99

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood (2006) 4.92

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol (2007) 4.61

Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res (2003) 4.55

Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature (1985) 3.50

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood (2001) 2.25

HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol (2007) 2.16

Retinoid therapy of high-risk neuroblastoma. Cancer Lett (2003) 1.97

Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs (2007) 1.95

Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.95

BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect. Nat Med (2003) 1.67

Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res (2007) 1.62

Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro. Med Pediatr Oncol (2000) 1.10

Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide. J Natl Cancer Inst (2007) 1.06

Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro. Clin Cancer Res (2003) 0.99

All-trans-retinoic acid-induced apoptosis in human medulloblastoma: activation of caspase-3/poly(ADP-ribose) polymerase 1 pathway. Clin Cancer Res (2003) 0.91

Articles by these authors

Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med (2011) 11.01

The TOR pathway: a target for cancer therapy. Nat Rev Cancer (2004) 9.02

The genetic landscape of the childhood cancer medulloblastoma. Science (2010) 8.34

Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multi-institutional collaborative project. Med Pediatr Oncol (2002) 8.03

Identification of ALK as a major familial neuroblastoma predisposition gene. Nature (2008) 7.38

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med (2010) 6.34

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med (2014) 5.37

The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer (2007) 5.28

Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol (2009) 5.12

Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med (2005) 4.92

The genetic landscape of high-risk neuroblastoma. Nat Genet (2013) 4.71

Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res (2009) 4.53

The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med (2004) 4.28

Adjustment of genomic waves in signal intensities from whole-genome SNP genotyping platforms. Nucleic Acids Res (2008) 4.22

Copy number variation at 1q21.1 associated with neuroblastoma. Nature (2009) 4.10

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol (2013) 3.70

Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood (2010) 3.66

Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood (2011) 3.40

Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet (2012) 3.38

Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol (2005) 3.36

Biology and therapeutic advances for pediatric osteosarcoma. Oncologist (2004) 3.34

STAC: A method for testing the significance of DNA copy number aberrations across multiple array-CGH experiments. Genome Res (2006) 3.21

Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res (2004) 3.20

Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood (2004) 3.13

Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer (2010) 2.99

Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med (2014) 2.92

The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet (2013) 2.89

Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia. Blood (2009) 2.86

A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol Cancer Res (2008) 2.77

Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell (2009) 2.60

The majority of total nuclear-encoded non-ribosomal RNA in a human cell is 'dark matter' un-annotated RNA. BMC Biol (2010) 2.59

Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc (2007) 2.54

Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA (2012) 2.49

Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat Genet (2009) 2.47

Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res (2006) 2.42

A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations. Mol Cancer Ther (2007) 2.35

Carboplatin-associated ototoxicity in children with retinoblastoma. J Clin Oncol (2012) 2.32

Rapamycins: mechanism of action and cellular resistance. Cancer Biol Ther (2003) 2.31

Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res (2005) 2.31

mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1α. Mol Cell (2010) 2.27

The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood (2005) 2.25

Acetylcholinesterase inhibitors from plants. Phytomedicine (2007) 2.25

Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol (2013) 2.25

Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol (2003) 2.24

Leads from Indian medicinal plants with hypoglycemic potentials. J Ethnopharmacol (2006) 2.21

Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nat Genet (2013) 2.21

Integrative genomics identifies LMO1 as a neuroblastoma oncogene. Nature (2010) 2.21

Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer (2004) 2.20

Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther (2006) 2.19

Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature (2006) 2.12

Crystal structure of human carboxylesterase 1 complexed with the Alzheimer's drug tacrine: from binding promiscuity to selective inhibition. Chem Biol (2003) 2.05

Genomic copy number determination in cancer cells from single nucleotide polymorphism microarrays based on quantitative genotyping corrected for aneuploidy. Genome Res (2009) 2.02

The role of chest computed tomography (CT) as a surveillance tool in children with high-risk neuroblastoma. Pediatr Blood Cancer (2015) 1.97

Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Sci Transl Med (2011) 1.96

Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.95

Therapy for osteosarcoma: where do we go from here? Paediatr Drugs (2008) 1.95

The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev (2008) 1.93

Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway. Cancer Res (2004) 1.93

Analysis of prognostic factors in ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital studies. Cancer (2007) 1.93

Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol (2010) 1.92

A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin Cancer Res (2006) 1.91

Lost in translation: dysregulation of cap-dependent translation and cancer. Cancer Cell (2004) 1.91

RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proc Natl Acad Sci U S A (2011) 1.90

IGF-I mediated survival pathways in normal and malignant cells. Biochim Biophys Acta (2006) 1.88

Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma. Oncogene (2005) 1.86

Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach. J Clin Oncol (2005) 1.85

Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1). Mol Cell (2003) 1.84

Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res (2008) 1.84